United States: Updates On Recent Foreign Approvals And Launches - Goodwin Procter LLP
Friday, 9 June 2023
On May 26, 2023, the European Commission granted the marketing authorization to Samsung Bioepis for EPYSQLI, a biosimilar referencing SOLIRIS developed by Alexion for the treatment of the paroxysmal nocturnal hemoglobinuria that had global sales of approximately $5 trillion last year.
|
||||
You Might Like |
||||
